Josep Tabernero Selected Research

Exanthema (Rash)

2/2015	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
7/2014	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
1/2013	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
1/2011	Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josep Tabernero Research Topics

Disease

238	Neoplasms (Cancer) 04/2024 - 06/2004
169	Colorectal Neoplasms (Colorectal Cancer) 05/2024 - 06/2004
35	Colonic Neoplasms (Colon Cancer) 02/2022 - 06/2004
32	Neoplasm Metastasis (Metastasis) 04/2024 - 12/2007
29	Adenocarcinoma 12/2023 - 09/2006
24	Disease Progression 12/2023 - 06/2004
17	Stomach Neoplasms (Stomach Cancer) 01/2023 - 09/2006
16	Neutropenia 01/2023 - 06/2004
14	Breast Neoplasms (Breast Cancer) 10/2023 - 08/2007
14	Carcinoma (Carcinomatosis) 01/2023 - 09/2006
13	Pancreatic Neoplasms (Pancreatic Cancer) 04/2023 - 01/2011
12	Microsatellite Instability 01/2024 - 03/2011
10	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 02/2012
10	COVID-19 01/2023 - 01/2020
10	Carcinogenesis 01/2019 - 09/2008
9	Fatigue 04/2024 - 01/2013
8	Melanoma (Melanoma, Malignant) 01/2024 - 03/2011
7	Hypertension (High Blood Pressure) 01/2023 - 01/2011
7	Stomatitis 01/2023 - 04/2008
6	Nausea 12/2023 - 01/2015
6	Diarrhea 01/2023 - 01/2007
5	Asthenia 04/2024 - 01/2008
5	Vomiting 01/2023 - 01/2007
5	Rectal Neoplasms (Rectal Cancer) 01/2017 - 12/2008
5	Febrile Neutropenia 05/2015 - 06/2004
4	Lung Neoplasms (Lung Cancer) 01/2023 - 08/2010
4	Cholangiocarcinoma 01/2023 - 08/2015
4	Thyroid Neoplasms (Thyroid Cancer) 01/2020 - 12/2009
4	Anemia 01/2020 - 03/2015
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2017 - 03/2006
4	Exanthema (Rash) 02/2015 - 01/2011
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2013 - 06/2007
3	Abdominal Pain (Pain, Abdominal) 04/2023 - 11/2018

Drug/Important Bio-Agent (IBA)

59	Biomarkers (Surrogate Marker)IBA 08/2023 - 09/2006
49	Cetuximab (Erbitux)FDA Link 01/2024 - 08/2005
48	Oxaliplatin (Eloxatin)FDA LinkGeneric 03/2024 - 06/2004
41	ErbB Receptors (EGF Receptor)IBA 01/2024 - 08/2005
35	Fluorouracil (Carac)FDA LinkGeneric 12/2023 - 06/2004
29	Leucovorin (Folinic Acid)FDA Link 12/2023 - 06/2004
28	Monoclonal AntibodiesIBA 01/2024 - 08/2005
25	Irinotecan (Camptosar)FDA LinkGeneric 03/2024 - 01/2008
23	Bevacizumab (Avastin)FDA Link 03/2024 - 08/2010
22	Proteins (Proteins, Gene)FDA Link 04/2024 - 03/2008
20	Panitumumab (Vectibix)FDA Link 03/2024 - 12/2008
15	Immune Checkpoint InhibitorsIBA 01/2024 - 05/2016
15	Gemcitabine FDA Link 10/2023 - 10/2013
13	Tyrosine Kinase InhibitorsIBA 01/2023 - 08/2005
12	trifluridine tipiracil drug combinationIBA 03/2024 - 05/2015
12	AntibodiesIBA 02/2024 - 08/2010
12	pembrolizumabIBA 01/2024 - 03/2017
12	RamucirumabIBA 10/2021 - 01/2014
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 03/2007
11	Trastuzumab (Herceptin)FDA Link 12/2023 - 08/2010
11	encorafenibIBA 10/2023 - 01/2017
11	130-nm albumin-bound paclitaxelIBA 10/2023 - 10/2013
11	Capecitabine (Xeloda)FDA Link 01/2023 - 06/2004
10	afliberceptIBA 01/2022 - 10/2012
8	regorafenibIBA 01/2023 - 01/2013
8	LigandsIBA 01/2023 - 12/2014
8	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 12/2015
7	Cisplatin (Platino)FDA LinkGeneric 12/2023 - 11/2008
7	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2011
6	atezolizumabIBA 05/2024 - 03/2017
6	binimetinibIBA 12/2023 - 10/2019
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2023 - 12/2013
6	Everolimus FDA Link 04/2021 - 04/2008
6	XELOXIBA 11/2015 - 06/2004
5	PlatinumIBA 12/2023 - 08/2008
5	CateninsIBA 01/2023 - 09/2011
5	Messenger RNA (mRNA)IBA 01/2023 - 04/2013
5	Dihydrotachysterol (AT 10)IBA 12/2018 - 01/2004
5	Cell-Free Nucleic AcidsIBA 01/2018 - 12/2011
5	Mechanistic Target of Rapamycin Complex 1IBA 01/2017 - 05/2011
5	Phosphotransferases (Kinase)IBA 07/2015 - 07/2009
4	Transaminases (Aminotransferases)IBA 04/2024 - 05/2007
4	Circulating Tumor DNAIBA 10/2023 - 01/2018
4	pertuzumabIBA 01/2023 - 10/2018
4	erdafitinibIBA 01/2023 - 07/2015
4	VemurafenibIBA 01/2023 - 03/2011
4	AlbuminsIBA 01/2021 - 03/2012
4	futuximabIBA 01/2020 - 06/2015
4	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 07/2015
4	MTOR InhibitorsIBA 12/2017 - 08/2010
4	Phosphatidylinositols (Phosphatidylinositol)IBA 06/2015 - 07/2013
3	Carcinoembryonic AntigenIBA 02/2024 - 01/2017
3	Transforming Growth Factor beta (TGF-beta)IBA 10/2023 - 03/2008
3	napabucasinIBA 04/2023 - 04/2019
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 05/2007
3	Phenobarbital (Luminal)FDA Link 01/2023 - 08/2014
3	Oxygen (Dioxygen)IBA 11/2022 - 01/2022

Therapy/Procedure

148	Therapeutics 04/2024 - 06/2004
68	Drug Therapy (Chemotherapy) 12/2023 - 06/2007
19	Immunotherapy 10/2023 - 01/2016
16	Adjuvant Chemotherapy 12/2023 - 06/2006
12	Precision Medicine 12/2022 - 07/2013
8	Radiotherapy 01/2020 - 12/2008
5	Chemoradiotherapy 01/2018 - 12/2008
5	Operative Surgical Procedures 01/2018 - 07/2007
3	Aftercare (After-Treatment) 10/2023 - 05/2012
3	Neoadjuvant Therapy 01/2023 - 05/2012